Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Booo!!!
So you have nothing in common with common shareholder you're saying. Got it.
If you really believe that you should be more concerned with why a big money company hasn't bought this tiny broke company to save all those lives.
Good line at the coffee-snack bar?
A lot of interesting ASCO presentations today. What's going on over at the NWBO booth?
That is total BS. One observation I've made here is that pumpers seem to take everything at face value if it's coming from a perceived authority figure. It all actually makes sense.
And no whistleblowers suddenly died either.
You guys are wandering in the dark.
Well, a least I don't have to modify your handle, DrugRunner. If the shoe fits...
Go tell that to Gamma Knife patients.
The vaccine did squat. My friends were nearly all vaccinated and kept getting Covid. And, don't give us the milder symptoms bs. If it benefited anyone it was those who were immune compromised and the elderly.
The spike was supposed to remain in the arm but instead ended up in many organs.
Children were most susceptible to the vaccine even though their Covid mortality rate was nearly zero. Foolish mandate.
You have no idea what really went down in China so please just stop.
>>There was a massive trial and the side-effects, despite the right-wing desire to politicize the pandemic and monetize it, have been overstated given how many people died from it and how long China took to recover from it for lack of a modern vaccine.
That's what I said too. We'll see if yours last.
Anyway, there's a reason LP moved to the OTC and never speaks to her retail base, and instead lets her old GC do the talking. She likely has always known there isn't a chance for approval and can't get caught with a question about all of it. Meanwhile Specials revenue trickles in so use it to help build out her private CDMO.
Note: You let Bio's stand.
That's why they call you BioHarm. Doubting a new experimental vaccine for a cold virus with its makers insisting on being held harmless, is not "AntiVax", you idiot.
Helped build Advent though. 🧐
No dancing around governance here, DanishDancer. Please return to your retail influencer blog. Thanks.
We're trying to have an adult conversation here, KIPK, so please come back later. Thanks.
Every treatment is palliative unless it deals with the cancer stem cell itself.
But we'll see if mRNA survives the onslaught of lawsuits likely coming. It wasn't ready for primetime, IMO.
https://metatron.substack.com/cp/145121586
Cost for radiation treatment is low and the tech gets better every day.
Like I've told you all here many times, there are plenty of GBM trials where the government won't need to pay for them. Right or wrong, mRNA is the government's darling. Watch and learn.
>>Last year, the Government signed an agreement with BioNTech to provide up to 10,000 patients with precision cancer immunotherapies by 2030.
BioNTech has already begun conducting clinical trials in the UK, and the NHS launch pad is helping to accelerate the identification of eligible patients for those trials in England.
Nobody should want to read this crap when we all know you'll be claiming to buy more right after those sour grapes are delivered.
>>I hope no sour grapes by you if it happens in June.
Meanwhile whiny rhoid always pans management while constantly claiming to be buying more. Can't make up.
Please no rants and hearsay. Just show us Flaskworks progress in the latest filing. Long way to go.
How come you disciples never ask AI anything about governance?
I agree, and said as much when the 10k first came out. But that doesn't stop NWBO from simply saying it was "accepted for review". Yup more games, agree again.
>>EQRx – a focused on expanding access to innovative medicines – has announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has accepted a marketing authorisation application (MAA) for sugemalimab.
>>Melanie Nallicheri, president and chief executive officer at EQRx, reflected: “With the acceptance of this application, we now have two investigational therapies under review with the MHRA in non-small cell lung cancer,
Maybe, maybe not. Perhaps it's up to the company how exactly they want to phrase it. I'd much prefer reading "Acceptance" than a second "Validation.
>>EQRx – a focused on expanding access to innovative medicines – has announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has accepted a marketing authorisation application (MAA) for sugemalimab.
>>Melanie Nallicheri, president and chief executive officer at EQRx, reflected: “With the acceptance of this application, we now have two investigational therapies under review with the MHRA in non-small cell lung cancer,
Careful using "Accepted", NWBO only confirmed it was "Validated" (twice). I'll have to go with it but remain skeptical.
Like I said, he's Alfred E.
Easy. Because the disciples don't like what you're reporting.
Or maybe NICE didn't look under their Advent file?? LOL
Les is General Counsel not the CFO. There's a reason the company parades the GC out there instead of LP. Ex may recall PPHM was unusual in that way too with its GC.
So, now we NIH saying to hopefully expect cancer vaccines in the UK within five years. We have Les saying to hopefully hear something from MHRA in the Fall. And, we have NICE saying they haven't even received anything from NWBO. Should be a fun summer. Well, at least we have the $40M True-up redo to watch. Eye rolls.
You are an Excuse machine.
No they have not. There's still zero evidence that Flaskworks works or will save them any money. It's an endless work in progress. Add to it all the complications of transportation, scheduling, and possible problems arising with batches instead of single patient processing. It'll take years and years to find any savings if ever.
>>yet they still found a way to overcome false assertions
AKA limited use.
>>However, it's important to note that funding decisions by the CDF are made on a case-by-case basis, considering the available evidence and the potential benefits to patients.
Biotechs and BP do it every day. Their manufacturing capability grows with demand. You're pretending like there going to be some onslaught of demand for L day one as an excuse for going nowhere with revenues. It's a joke. Add to it you're ignoring LP's own words from ten years ago about being cost effective. What's wrong with you people? Have to be shills.
STOP IT ALREADY!
>>finding enough qualified people
It's a joke. The trial ended five years ago. LP told the Street ten years ago there were no issues with manufacturing cost. Goodnight.
Ouch!!! Dragging it out, as predicted. No rush for MHRA nod now. Just sit on it please. See you in 2025.